Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

(2013) Kenneth Cusi et al.   JOURNAL OF HEPATOLOGY

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

(2012) J. Shen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis

(2012) Yusuf Yilmaz et al.   CLINICA CHIMICA ACTA

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease

(2012) Chan Wah-Kheong et al.   Hepatology International

Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers

(2012) Jiayun Shen et al.   JOURNAL OF HEPATOLOGY

An apoptosis panel for nonalcoholic steatohepatitis diagnosis

(2010) Tarek I. Abu-Rajab Tamimi et al.   JOURNAL OF HEPATOLOGY

A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

(2010) Zobair M. Younossi et al.   OBESITY SURGERY

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

(2009) Ariel E. Feldstein et al.   HEPATOLOGY

Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients

(2008) Dima L. Diab et al.   Clinical Gastroenterology and Hepatology